Difference between revisions of "Antidepressants and other psychiatric medications in cancer care"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (spacing)
(half-lives)
Line 8: Line 8:
 
!Starting dose
 
!Starting dose
 
!Target dose
 
!Target dose
 +
!Half-life
 
!Interactions
 
!Interactions
 
!Side effects
 
!Side effects
Line 17: Line 18:
 
|10 mg
 
|10 mg
 
|20-40 mg
 
|20-40 mg
 +
|35 hours
 
|Mild 2D6 inhibition
 
|Mild 2D6 inhibition
 
Platelet dysfunction
 
Platelet dysfunction
Line 28: Line 30:
 
|5 mg
 
|5 mg
 
|10-20 mg
 
|10-20 mg
 +
|27-32 hours; 50% greater in elderly patients
 
|Mild 2D6 inhibition
 
|Mild 2D6 inhibition
 
Platelet dysfunction
 
Platelet dysfunction
Line 39: Line 42:
 
|10 mg
 
|10 mg
 
|20-60 mg
 
|20-60 mg
 +
|4-6 days (fluoxetine); 9.3 days (norfluoxetine)
 
|CYP450 2D6 inhibition
 
|CYP450 2D6 inhibition
 
Very long half-life and multiple drug interactions
 
Very long half-life and multiple drug interactions
Line 50: Line 54:
 
|50 mg
 
|50 mg
 
|150-200 mg
 
|150-200 mg
 +
|26 hours
 
|Weak 2D6 inhibition
 
|Weak 2D6 inhibition
 
Inhibits platelet function
 
Inhibits platelet function
Line 60: Line 65:
 
|37.5 mg
 
|37.5 mg
 
|150 mg
 
|150 mg
 +
|5 hours (parent drug); 11 hours (active metabolite)
 
|2D6 inhibition
 
|2D6 inhibition
 
Reduces platelet function
 
Reduces platelet function
Line 73: Line 79:
 
XR: 150 mg
 
XR: 150 mg
 
|150-300 mg
 
|150-300 mg
 +
|21 hours
 
|Strong 2D6 inhibition
 
|Strong 2D6 inhibition
 
|Seizure risk (Black box)
 
|Seizure risk (Black box)
Line 84: Line 91:
 
|7.5 mg  
 
|7.5 mg  
 
|30-40 mg
 
|30-40 mg
 +
|20-40 hours
 
|Neutropenia reported
 
|Neutropenia reported
 
2D6 substrate
 
2D6 substrate
Line 95: Line 103:
 
|25-50 mg
 
|25-50 mg
 
|50-100 mg
 
|50-100 mg
 +
|3-6 hours (first phase); 5-9 hours (second phase)
 
|3A4 substrate
 
|3A4 substrate
 
|Sedation
 
|Sedation
Line 107: Line 116:
 
|10-25 mg
 
|10-25 mg
 
|Check blood levels and EKG
 
|Check blood levels and EKG
 +
|12-27 hours
 
|Strong 2D6 inhibition
 
|Strong 2D6 inhibition
 
Rare agranulocytosis
 
Rare agranulocytosis
Line 119: Line 129:
 
|10-25 mg
 
|10-25 mg
 
|Check blood levels and EKG
 
|Check blood levels and EKG
 +
|11-25 hours
 
|Strong 2D6 inhibition
 
|Strong 2D6 inhibition
 
Rare agranulocytosis
 
Rare agranulocytosis
Line 131: Line 142:
 
|10-25 mg
 
|10-25 mg
 
|Check blood levels and EKG
 
|Check blood levels and EKG
 +
|18-44 hours
 
|Strong 2D6 inhibition
 
|Strong 2D6 inhibition
 
Rare agranulocytosis
 
Rare agranulocytosis
Line 142: Line 154:
 
|100 mg
 
|100 mg
 
|Large range from 300-3600 mg
 
|Large range from 300-3600 mg
 +
|5-7 hours
 
|Renal excreted (i.e. not metabolized)
 
|Renal excreted (i.e. not metabolized)
 
|Sedation
 
|Sedation
Line 150: Line 163:
 
|25 mg
 
|25 mg
 
|200 mg (for psych)
 
|200 mg (for psych)
 +
|14 hours with enzyme-inducing anticonvulsants (EIA); 59 hours with valproic acid (VPA); 28 hours with EIA & VPA
 
|No weight gain
 
|No weight gain
 
Other anti-seizure medications can double blood levels of lamotrigine
 
Other anti-seizure medications can double blood levels of lamotrigine
Line 160: Line 174:
 
|5 mg
 
|5 mg
 
|15-20 mg
 
|15-20 mg
 +
|75 hours (CYP2D6 extensive metabolizers); 146 hours CYP2D6 poor metabolizers)
 
|QTc prolongation may be less than other atypicals
 
|QTc prolongation may be less than other atypicals
 
No CYP450 inhibition
 
No CYP450 inhibition
Line 173: Line 188:
 
|2.5-5 mg
 
|2.5-5 mg
 
|10 mg
 
|10 mg
 +
|21-54 hours
 
|QTc prolongation
 
|QTc prolongation
 
|Sedation
 
|Sedation
Line 185: Line 201:
 
|25-50 mg
 
|25-50 mg
 
|100-300 mg
 
|100-300 mg
 +
|6-7 hours
 
|3A4 substrate, limited drug/drug interactions
 
|3A4 substrate, limited drug/drug interactions
 
QTc prolongation
 
QTc prolongation
Line 195: Line 212:
 
|5 mg
 
|5 mg
 
|5-10 mg
 
|5-10 mg
 +
|2.5-3.1 hours
 
|Alcohol interaction
 
|Alcohol interaction
 
Hepatic metabolism
 
Hepatic metabolism

Revision as of 17:42, 10 July 2012

Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.

Medication Class Indication Starting dose Target dose Half-life Interactions Side effects
Citalopram (Celexa) SSRI Anxiety

Depression

10 mg 20-40 mg 35 hours Mild 2D6 inhibition

Platelet dysfunction

Nausea

fatigue

Escitalopram (Lexapro) SSRI Anxiety

Depression

5 mg 10-20 mg 27-32 hours; 50% greater in elderly patients Mild 2D6 inhibition

Platelet dysfunction

Nausea

fatigue

Fluoxetine (Prozac) SSRI Depression

Anxiety

10 mg 20-60 mg 4-6 days (fluoxetine); 9.3 days (norfluoxetine) CYP450 2D6 inhibition

Very long half-life and multiple drug interactions

Nausea

Sedation

Sertraline (Zoloft) SSRI Depression

Anxiety

50 mg 150-200 mg 26 hours Weak 2D6 inhibition

Inhibits platelet function

Nausea
Venlafaxine (Effexor XR) SNRI Depression

Anxiety

37.5 mg 150 mg 5 hours (parent drug); 11 hours (active metabolite) 2D6 inhibition

Reduces platelet function

Hypertension

Nausea Flu-like withdrawal

Bupropion (Wellbutrin/Zyban) Other antidepressant Depression

Activating

SR: 50-75 mg

XR: 150 mg

150-300 mg 21 hours Strong 2D6 inhibition Seizure risk (Black box)

Anxiety

Mirtazapine (Remeron) Other antidepressant Anxiety

Depression Insomnia

7.5 mg 30-40 mg 20-40 hours Neutropenia reported

2D6 substrate

Weight gain

Sedation

Trazodone (Desyrel) Other antidepressant Anxiety

Insomnia

25-50 mg 50-100 mg 3-6 hours (first phase); 5-9 hours (second phase) 3A4 substrate Sedation

Nausea

Desipramine (Norpramin) Tricyclic Depression

Anxiety Insomnia Boost pain control

10-25 mg Check blood levels and EKG 12-27 hours Strong 2D6 inhibition

Rare agranulocytosis

Anticholinergic symptoms
Imipramine (Tofranil) Tricyclic Depression

Anxiety Insomnia Boost pain control

10-25 mg Check blood levels and EKG 11-25 hours Strong 2D6 inhibition

Rare agranulocytosis

Anticholinergic symptoms
Nortriptyline (Pamelor) Tricyclic Depression

Anxiety Insomnia Boost pain control

10-25 mg Check blood levels and EKG 18-44 hours Strong 2D6 inhibition

Rare agranulocytosis

Anticholinergic symptoms
Gabepentin (Neurontin) Anti-seizure Pain control

Anxiety Insomnia

100 mg Large range from 300-3600 mg 5-7 hours Renal excreted (i.e. not metabolized) Sedation
Lamotrigine (Lamictal) Anti-seizure Elevates mood 25 mg 200 mg (for psych) 14 hours with enzyme-inducing anticonvulsants (EIA); 59 hours with valproic acid (VPA); 28 hours with EIA & VPA No weight gain

Other anti-seizure medications can double blood levels of lamotrigine

Stevens-Johnson with any change in dose (Black box)
Aripiprazole (Abilify) Antipsychotic Agitation

Anxiety

5 mg 15-20 mg 75 hours (CYP2D6 extensive metabolizers); 146 hours CYP2D6 poor metabolizers) QTc prolongation may be less than other atypicals

No CYP450 inhibition Rare agranulocytosis

Less weight gain

Extrapyramidal symptoms including akathisia and risk of tardive dyskinesia when mixed with prochlorperazine (Compazine) or metoclopramide (Reglan)

Olanzapine (Zyprexa) Antipsychotic Agitation

Insomnia Anxiety

2.5-5 mg 10 mg 21-54 hours QTc prolongation Sedation

Weight gain

Quetiapine (Seroquel) Antipsychotic Nausea

Anxiety Insomnia Agitation

25-50 mg 100-300 mg 6-7 hours 3A4 substrate, limited drug/drug interactions

QTc prolongation

Sedation

Weight gain

Zolpidem (Ambien) Insomnia Insomnia 5 mg 5-10 mg 2.5-3.1 hours Alcohol interaction

Hepatic metabolism

Sedation

Dizziness Parasomnias

Information adapted from a table created by Christine Wittmann, MD and Laurie Rosenblatt, MD. Used with permission.